tetano
Editor, Senior Moderator
J Infect Chemother
. 2023 May 18;S1341-321X(23)00117-4.
doi: 10.1016/j.jiac.2023.05.007. Online ahead of print. Judicious ending of isolation based on reverse transcription-polymerase chain reaction (RT-PCR) cycle threshold only for patients with coronavirus disease 2019 (COVID-19) requiring in-hospital therapy for longer than 20 days after symptom onset
Yasushi Murakami[SUP] 1 [/SUP], Hitoshi Ogashiwa[SUP] 2 [/SUP], Yasuhiro Nozaki[SUP] 3 [/SUP], Takashi Ueda[SUP] 4 [/SUP], Kazuhiko Nakajima[SUP] 5 [/SUP], Mika Morosawa[SUP] 6 [/SUP], Miki Doi[SUP] 7 [/SUP], Miyuki Makino[SUP] 8 [/SUP], Yoshio Takesue[SUP] 9 [/SUP]
Affiliations
Background: For patients with coronavirus disease 2019 (COVID-19) requiring hospitalization, extending isolation is warranted. As a cautious protocol, ending isolation based on polymerase chain reaction cycle threshold (Ct) value was introduced for patients requiring therapy for >20 days after symptom onset.
Method: We compared a Ct-based strategy using Smart Gene® between March 2022 and January 2023 with a preceding control period (March 2021 to February 2022) when two consecutive negative reverse transcription-polymerase chain reaction tests using FilmArray® were required for ending isolation. Ct was evaluated on day 21, and ending isolation was permitted in patients with Ct ≥ 38. Although patients with Ct 35-37 were transferred to a non-COVID-19 ward, isolation was continued.
Results: The duration of stay on a COVID-19 ward in the Ct group was 9.7 days shorter than that in controls. The cumulative number of tests was 3.7 in controls and 1.2 in the Ct group. There was no nosocomial transmission after ending isolation in either group. The number of days from symptom onset to testing was 20.7 ± 2.1 in Ct group, and five patients had Ct < 35, nine Ct 35-37, and 71 Ct ≥ 38. No patients were moderately or severely immunocompromised. Steroid use was an independent risk factor for prolonged low Ct (odds ratio 9.40, 95% confidence interval 2.31-38.15, p = 0.002) CONCLUSIONS: The efficacy of ending isolation based on Ct values could improve bed utilization without the risk of transmission among patients with COVID-19 requiring therapy for >20 days after symptom onset.
Keywords: Coronavirus disease 2019; Cycle threshold; Isolation; Reverse transcription–polymerase chain reaction; Severe acute respiratory syndrome coronavirus 2.
. 2023 May 18;S1341-321X(23)00117-4.
doi: 10.1016/j.jiac.2023.05.007. Online ahead of print. Judicious ending of isolation based on reverse transcription-polymerase chain reaction (RT-PCR) cycle threshold only for patients with coronavirus disease 2019 (COVID-19) requiring in-hospital therapy for longer than 20 days after symptom onset
Yasushi Murakami[SUP] 1 [/SUP], Hitoshi Ogashiwa[SUP] 2 [/SUP], Yasuhiro Nozaki[SUP] 3 [/SUP], Takashi Ueda[SUP] 4 [/SUP], Kazuhiko Nakajima[SUP] 5 [/SUP], Mika Morosawa[SUP] 6 [/SUP], Miki Doi[SUP] 7 [/SUP], Miyuki Makino[SUP] 8 [/SUP], Yoshio Takesue[SUP] 9 [/SUP]
Affiliations
- PMID: 37209841
- DOI: 10.1016/j.jiac.2023.05.007
Background: For patients with coronavirus disease 2019 (COVID-19) requiring hospitalization, extending isolation is warranted. As a cautious protocol, ending isolation based on polymerase chain reaction cycle threshold (Ct) value was introduced for patients requiring therapy for >20 days after symptom onset.
Method: We compared a Ct-based strategy using Smart Gene® between March 2022 and January 2023 with a preceding control period (March 2021 to February 2022) when two consecutive negative reverse transcription-polymerase chain reaction tests using FilmArray® were required for ending isolation. Ct was evaluated on day 21, and ending isolation was permitted in patients with Ct ≥ 38. Although patients with Ct 35-37 were transferred to a non-COVID-19 ward, isolation was continued.
Results: The duration of stay on a COVID-19 ward in the Ct group was 9.7 days shorter than that in controls. The cumulative number of tests was 3.7 in controls and 1.2 in the Ct group. There was no nosocomial transmission after ending isolation in either group. The number of days from symptom onset to testing was 20.7 ± 2.1 in Ct group, and five patients had Ct < 35, nine Ct 35-37, and 71 Ct ≥ 38. No patients were moderately or severely immunocompromised. Steroid use was an independent risk factor for prolonged low Ct (odds ratio 9.40, 95% confidence interval 2.31-38.15, p = 0.002) CONCLUSIONS: The efficacy of ending isolation based on Ct values could improve bed utilization without the risk of transmission among patients with COVID-19 requiring therapy for >20 days after symptom onset.
Keywords: Coronavirus disease 2019; Cycle threshold; Isolation; Reverse transcription–polymerase chain reaction; Severe acute respiratory syndrome coronavirus 2.